Rank/RANKL/OPG: Literature review

Acta Reumatologica Portuguesa

Volumn 36, Issue 3, 2011, Pages 209-218

  Silva, I ^a   Branco, J C ^a,b  

^a Centro Hospitalar de Lisboa Ocidental   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Bone formation; Osteoclast; Osteoprotegerin; RANK; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

HUMAN; PHYSIOLOGY; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION;

HUMANS; RANK LIGAND; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 84858684687     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Tat ST, Pelletier JP, Velasco CR, Padrines M, Pelletier JM. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 2009;58:29-40.
2. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of biochemistry and biophysics 2008;473:139-146.
3. Boyce BF, Xing L. Biology of RANK, RANKL, an osteoprotegerin. Arthritis research and therapy 2007:1-7.
4. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kB (RANK)/RANK ligand/Osteoprotegerin: clinical implications. The Journal of Clinical Endocrinology and Metabolism 2007;92:4514-4521.
5. Whyte MP, Mumm S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskel Neuron Interact 2004;4:254-267.
6. Caetano-Lopes J, Canhão H, Fonseca JE. Osteoblasts and bone formation. Acta Reumatológica Portuguesa 2007;32:103-110.
7. Kamiya N, Ye L, Kobayashi T et al. BMP signaling nega tively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008;135:3801-3811.
8. Geusens P. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clinical intervention in aging 2009;4:241-250.
9. Tao J, Chen S, Lee B. Alteration of Notch signaling in skeletal development and disease. Ann N Y Acad Sci 2010;1192:257-268.
10. Engin F, Lee B. NOTCHing the bone: Insights into multi-functionality. Bone 2010; 46:274-280.
11. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membranebound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
12. Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood 2011; 117:3648-3657.
13. Sabacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39:960-962.
14. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 2006;45:1068-1076.
15. Ainola M, Mandelin J, Liljeström M, Konttinen YT, Salo J. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin Exp Rheumatol 2008;26:240-246.
16. Kim YG, Lee CK, Oh JS et al. Effect of interleukin-32 gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum 2010; 62:515-23.
17. Hein GE, Meister M, Oelzner P, Franke S. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparision to non-destructive chronic arthritis. Rheumatol Int 2008;28:765-769.
18. Assmann G, Koenig J, Pfreundschuh M, et al. Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study. J Rheumatol 2010;37:900-904.
19. Haynes D, Crotti T, Weedon H et al. Modulation of RANKL and Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis and Rheumatism 2008;59:911-920.
20. Haynes DR, Barg E, Crotti TN et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003;42:123-134.
21. Walsh NC, Gravallese EM. Bone remodeling in rheumatic diseases: a question of balance. Immunol Rev 2010;233:301-312.
22. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis and Rheumatism 2008;58:718-729.
23. Ominsky MS, Li X, Asuncion FJ et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. Journal of Bone and Mineral Research 2008;23:672-682.
24. Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with Sever knee osteoarthritis. Arthritis Rheum 2010;62:478-488.
25. Tat K, Pelletier JP, Vergés J et al. Chondroitin and glucosamine sulfate in combination decrease the proresorptive properties of human osteoarthritis subchondral bone osteoblasts. Arthritis Res Ther 2007;9: R117.
26. Pulsatelli L, Dolzani P, Silvestri T et al. Circulating RANKL/OPG in polymyalgia rheumatic. Clin Exp Rheumatol 2007;25:621-623.
27. Dovio A, Data V, Carignola R et al. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol 2008;35:2206-2213.
28. Rouster-Stevens KA, Langman CB, Price HE et al. RANKL:Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis and Rheumatism 2007;56:977-983.
29. Zdzisinnska B, Bjoarska-Junak A, Walter-Croneck A, Kandefer-Szerszen M. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells cocultured with myeloma cells. Arch Immunol Ther Exp 2010;58:153-163.
30. Spelling P, Bonfá E, Caparbo VF, Pereira RM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand J Rheumatol 2008;37:439-444.
31. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007;2007:75805.
32. D'Amelio P, Isaia G, Isaia GC. The osteo protegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009;32:6-9.
33. Panizo S, Cardus A, Encinas M et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4 dependent pathway. Journal of the American Heart Association-Circulation Research 2009; 104:1041-1048.
34. Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E. Does Osteoprotegerin or receptor activasilva tor of nuclear factor-kappa B ligand mediate the association between and coronary artery calcification? The J of Clin Endocrin and Metabolism 2008;93:2009-2012.
35. Moschen AR, Kaser A, Enrich B et al. The RANKL//OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-487.
36. Secchiero P, Corallini F, Pandolfi A et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006;169: 2236-2244.
37. Garcia-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol 2006;41:261-266.
38. Heymann MF, Riet A, Le Goff B et al. OPG, RANK and RANK ligand expression in thyroid lesions. REgul Pept 2008;148:46-53.
39. Fahrleitner-Pammer A, Dobnig H, Dimai HP et al. The effect of RANKL and OPG on bone mineral density in predialysis chronic renal failure. Clin Nephrol 2009;71:652-659.
40. Daoussi D, Andonopoulos AP, Liossis SNC. Wnt pathway and Il-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 2010;39:369-383.
41. Diarra D, Stolina M, Polzer K et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163.
42. Fujita KK; Janz S. Attenuation of WNT signaling by DKK-1 and-2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Molecular Cancer 2007;6:71:1-13.
43. Sanchez C, Gabay O, Salvat C, Henrotin YE, Berenbaum F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis Cartilage 2009;17:473-481.
44. Kim CH, Kim KH, Jacobs CR. Effects of high frequency loading on RANKL and OPG mRNA expression in ST-2 murine stromal cells. BMC musculoskeletal disorders 2009;109:1-7.
45. Subramaniam M, Hawse JR, Bruinsma ES et al. TGF-beta inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts. Biochem Biophys Res Commun 2010;392:72-76.
46. Chen ZK, Lv HS, Jiang J. LTB4 can stimulate human osteoclast differentiation dependent of RANKL. Artif Cells Blood Substit Immobil Biotechnol 2010;38:52-56.
47. Akiyama T, Dass Cr, Shinoda Y et al. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Re Commun 2010; 391:789-794.
48. Yang DC, Tsay HJ, Lin SY et al. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS ONE 2008;3:1-10.
49. Kim T, Kim K, Lee SH et al. Identification of LRRc17 as a negative regulator of receptor activator of NF-kB ligand (RANKL)-induced osteoclast differentiation. Journal of Biological Chemistry 2009;284:15308-15316.
50. Moen MD, Kean SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011;28:63-82.
51. Cumming SR, Martin JS, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM 2009;361:756-765.
52. Fili S, Karalaki M, Schaller B. Therapeutic implications of osteroprotegerin. Cancer cell international 2009;26:1-8.
53. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of pausal womenosteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
54. Van Poznak C, Cross SS, Saggese M, et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Patholog 2006;59:56-63.
55. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramaniam SP, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumours cell survival? Breast Cancer Res Treat 2005;92:207-215.